IFNG and melanoma: Gene expression profiling in melanoma patients treated with nivolumab (anti-PD1) alone or combined with Ipilimumab (anti-CTLA4) revealed that an IFNγ-driven gene signature was the most predictive feature for clinical responses to these immunotherapies [4].